[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:esophageal-adenocarcinoma:programmed-cell-death-1-ligand-1":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Esophageal Adenocarcinoma","Programmed Cell Death 1 Ligand 1",10,[8,16,23,29,35,41,48,54,61,67],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT04150640","Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric Adenocarcinoma",[12],"Phase 2","RECRUITING","2026-08-26T02:16:01.910993Z","2026-07-05T05:32:16.773838Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT07221149","A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)",[20],"Phase 2\u002FPhase 3","2026-08-26T02:16:38.053590Z","2026-07-05T05:32:16.664938Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT07554521","A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States",[12],"2026-08-26T02:15:00.557154Z","2026-05-13T02:55:06.723474Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT07432295","Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)",[12],"2026-08-26T02:15:45.413021Z","2026-05-05T02:43:29.196980Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT06203600","Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial",[20],"2026-08-26T02:17:28.381459Z","2026-05-05T02:43:28.966545Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":46,"content_modified":47},"NCT05677490","mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma",[45],"Phase 3","2026-08-26T02:16:44.178623Z","2026-05-05T02:43:27.998780Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT07392892","A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer",[20],"2026-08-26T02:15:17.167444Z","2026-04-29T02:57:57.159659Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":59,"content_modified":60},"NCT07205718","A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors",[58],"Phase 1\u002FPhase 2","2026-08-26T02:16:50.548894Z","2026-05-05T02:43:29.041246Z",{"nct_id":62,"title":63,"phases":64,"status":13,"updated_at":65,"content_modified":66},"NCT07290985","AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal Adenocarcinomas",[12],"2026-08-26T02:17:07.954622Z","2026-07-24T01:27:14.911516Z",{"nct_id":68,"title":69,"phases":70,"status":71,"updated_at":72,"content_modified":73},"NCT06628310","A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma",[12],"ACTIVE_NOT_RECRUITING","2026-08-03T02:10:37.231905Z","2026-05-05T02:43:28.668878Z"]